Агомелатин в терапии большого депрессивного расстройства: Список литературы

Статьи Sidney H. Kennedy , Sakina J. Rizvi
Предыдущий раздел | Содержание

Список использованной литературы

  1. Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819-34
  2. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 1997; 45: 5-17
  3. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55: 694-700
  4. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 2002; 25: 685-98
  5. Oquendo MA, Barrera A, Ellis SP, et al. Instability of symptoms in recurrent major depression: a prospective study. Am J Psychiatry 2004; 161: 255-61
  6. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157: 1-45
  7. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl. 1: S26-43
  8. Blier P, Keller MB, Pollack MH, et al. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry 2007; 68: e06
  9. Katon W, Rutter C, Ludman EJ, et al. A randomized trial of relapse prevention ofdepression in primary care. Arch Gen Psychiatry 2001; 58: 241-7
  10. Kennedy S, McIntyre R, Fallu A, et al. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002; 27: 269-80
  11. Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 176775
  12. Lepine JP, Caillard V, Bisserbe JC, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004; 161: 836-42
  13. Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull 2001; 57: 145-59
  14. Rost K, Nutting P, Smith JL, et al. Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care. BMJ 2002; 325: 934
  15. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293-306
  16. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653-61
  17. Akincigil A, Bowblis JR, Levin C, et al. Adherence to anti-depressant treatment among privately insured patients diagnosed with depression. Med Care 2007; 45: 363-9
  18. Bambauer KZ, Soumerai SB, Adams AS, et al. Provider and patient characteristics associated with antidepressant non-adherence: the impact of provider specialty. J Clin Psychiatry 2007; 68: 867-73
  19. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting: I. Beyond lack of efficacy and adverse events. J Clin Psychiatry 2001; 62 Suppl. 22: 30-3
  20. Katon W, Cantrell CR, Sokol MC, et al. Impact of anti-depressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005; 165: 2497-503
  21. Lawrenson RA, Tyrer F, Newson RB, et al. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000; 59: 149-57
  22. Lewis E, Marcus SC, Olfson M, et al. Patients' early discontinuation of antidepressant prescriptions. Psychiatr Serv 2004; 55: 494
  23. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006; 163: 101-8
  24. Eaddy MT, Druss BG, Sarnes MW, et al. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of anti-depressant therapy: results from a managed care administrative claims database. J Manag Care Pharm 2005; 11: 145-50
  25. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55: 1128-32
  26. Sheehan DV, Eaddy M, Sarnes M, et al. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine. J Clin Psychopharmacol 2004; 24: 544-8
  27. Sood N, Treglia M, Obenchain RL, et al. Determinants of antidepressant treatment outcome. Am J Manag Care 2000; 6: 1327-36
  28. Aikens JE, Kroenke K, Swindle RW, et al. Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. Gen Hosp Psychiatry 2005; 27: 229-36
  29. Aikens JE, Nease Jr DE, Klinkman MS. Explaining patients' beliefs about the necessity and harmfulness of anti-depressants. Ann Fam Med 2008; 6: 23-9
  30. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288: 1403-9
  31. Zivin K, Kales HC. Adherence to depression treatment in older adults: a narrative review. Drugs Aging 2008; 25: 559-71
  32. Brown C, Battista DR, Bruehlman R, et al. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005; 43: 1203-7
  33. Maidment R, Livingston G, Katona C. Just keep taking the tablets: adherence to antidepressant treatment in older people in primary care. Int J Geriatr Psychiatry 2002; 17:752-7
  34. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003; 25: 2289-304
  35. van Geffen EC, van Hulten R, Bouvy ML, et al. Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008; 42:218-25
  36. Nasrallah HA, Targum SD, Tandon R, et al. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv 2005; 56: 273-82
  37. Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int Clin Psychopharmacol 2006; 21 Suppl. 1: S17-20
  38. Millan MJ, Brocco M, Gobert A, et al. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005; 177: 448-58
  39. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxy-tryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-64
  40. Loci H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239-47
  41. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661-73
  42. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93-100
  43. European Medicines Agency. CMHP assessment report for valdoxan [online]. Available from URL: http:// www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/ H-915-en6.pdf. [Accessed 2009 Nov 20]
  44. Goodwin G, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a discontinuation syndrome. J Clin Psychiatry 2009; 70: 1128-37
  45. Lemoine P, Guilleminault CAE. Improvement in subjective sleep in major depressive disorder with a novel anti-depressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723-32
  46. Kasper S, Hajak G, Wulff C, et al. Efficacy of the novel anti-depressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71 (2): 109-20
  47. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008; 28: 329-33
  48. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-80
  49. Montejo A, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: an 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010; 24 (1): 111-20
  50. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 561-6
  51. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
  52. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9
  53. Guy W. ECDEU assessment manual for psychopharmacology: publication ADM 76-338. Rockville (MD): US Department of Health, Education and Welfare, National Institute of-Mental Health, 1976: 217-22
  54. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5
  55. Parrott AC, Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med 1978; 8: 325-9
  56. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-70
  57. Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007; 22: 28391
  58. Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19: 114-24
  59. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006; 51: 42
  60. Montejo AL, Garcia M, Espada M, et al., on behalf of the Spanish work group for the study of psychotropic-related sexual dysfunctions. Psychometric characteristics of the psychotropic-related sexual dysfunction questionnaire. Actas Esp Psiquiatr 2000; 28: 141-50
  61. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77-87
  62. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143: 415-26
  63. Kirsch I, Moore TJ, Scoboria A, et al. The emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 2002; 5: 1-14
  64. Melander H, Salmonson T, Abadie E, et al. A regulatory apologia: a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008; 18: 623-7
  65. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation anti-depressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58
  66. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63: 424-34
  67. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62: 1217-27
  68. Kennedy SH, Andersen HF, Lam RW. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009; 25: 161-75
  69. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149: 734-50
  70. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
  71. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-42
  72. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164: 739-52
  73. Staedt J, Hunerjager H, Ruther E, et al. Sleep cluster arousal analysis and treatment response to heterocyclic anti-depressants in patients with major depression. J Affect Disord 1998; 49: 221-7
  74. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 533-59
  75. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927-47
  76. Descamps A, Rousset C, Millan MJ, et al. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmacology (Berl) 2009; 205: 93-106
  77. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J Biol Psychiatry 2008;1-13
  78. Demyttenaere K, Albert A, Mesters P, et al. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry 2005; 66: 859-63
  79. Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008; 31: 851-65
  80. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry 2008; 69 Suppl. E1: 8-13
  81. Williams VS, Baldwin DS, Hogue SL. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry 2006; 67: 204-10
  82. Clayton AH, Pradko JK, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357-66
  83. Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002; 36: 1577-89
  84. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006; 114: 384-97
  85. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-60
  86. Предыдущий раздел | Содержание

1 ноября 2012 г.

МЕДИ РУ в: МЕДИ РУ на YouTube МЕДИ РУ в Twitter МЕДИ РУ на FaceBook МЕДИ РУ вКонтакте Рейтинг@Mail.ru Яндекс.Метрика